Search research articles
Contact Us
Filters
Showing results (31-40 of 76) with videos related to
Page
of 8
Sort By:
Journal of Medicinal Chemistry
|
March 4, 2025
Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with <i>MTAP</i> Deletion
Kevin M Cottrell, Kimberly J Briggs, Alice Tsai, et al.
Frontiers in Immunology
|
February 15, 2019
CD56<sup>dim</sup> CD16<sup>-</sup> Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-α
Lazar Vujanovic, Christopher Chuckran, Yan Lin, et al.
Journal of Translational Medicine
|
September 14, 2018
Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody
Jianqun Kou, Phillip R Musich, Ben Staal, et al.
The FEBS Journal
|
August 19, 2011
The prion protein binds thiamine
Rolando Perez-Pineiro, Trent C Bjorndahl, Mark V Berjanskii, et al.
Plos One
|
November 17, 2012
RAD001 enhances the potency of BEZ235 to inhibit mTOR signaling and tumor growth
Beat Nyfeler, Yan Chen, Xiaoyan Li, et al.
Neuroimage
|
April 10, 2013
Nuclear Overhauser enhancement (NOE) imaging in the human brain at 7T
Craig K Jones, Alan Huang, Jiadi Xu, et al.
Journal of Clinical Microbiology
|
November 26, 2020
Clinical Performance of the Point-of-Care cobas Liat for Detection of SARS-CoV-2 in 20 Minutes: a Multicenter Study
Glen Hansen, Jamie Marino, Zi-Xuan Wang, et al.
Cancer Cell
|
December 30, 2014
Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer
Carlotta Costa, Hiromichi Ebi, Miriam Martini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 25, 2019
Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation
Sabrina Baltschukat, Barbara Schacher Engstler, Alan Huang, et al.
Translational Oncology
|
January 5, 2025
TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers
Kimberly J Briggs, Kevin M Cottrell, Matthew R Tonini, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 76) with videos related to
Sort By:
Page
of 8
Journal of Medicinal Chemistry
|
March 4, 2025
Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with <i>MTAP</i> Deletion
Kevin M Cottrell, Kimberly J Briggs, Alice Tsai, et al.
Frontiers in Immunology
|
February 15, 2019
CD56<sup>dim</sup> CD16<sup>-</sup> Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-α
Lazar Vujanovic, Christopher Chuckran, Yan Lin, et al.
Journal of Translational Medicine
|
September 14, 2018
Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody
Jianqun Kou, Phillip R Musich, Ben Staal, et al.
The FEBS Journal
|
August 19, 2011
The prion protein binds thiamine
Rolando Perez-Pineiro, Trent C Bjorndahl, Mark V Berjanskii, et al.
Plos One
|
November 17, 2012
RAD001 enhances the potency of BEZ235 to inhibit mTOR signaling and tumor growth
Beat Nyfeler, Yan Chen, Xiaoyan Li, et al.
Neuroimage
|
April 10, 2013
Nuclear Overhauser enhancement (NOE) imaging in the human brain at 7T
Craig K Jones, Alan Huang, Jiadi Xu, et al.
Journal of Clinical Microbiology
|
November 26, 2020
Clinical Performance of the Point-of-Care cobas Liat for Detection of SARS-CoV-2 in 20 Minutes: a Multicenter Study
Glen Hansen, Jamie Marino, Zi-Xuan Wang, et al.
Cancer Cell
|
December 30, 2014
Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer
Carlotta Costa, Hiromichi Ebi, Miriam Martini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 25, 2019
Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation
Sabrina Baltschukat, Barbara Schacher Engstler, Alan Huang, et al.
Translational Oncology
|
January 5, 2025
TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers
Kimberly J Briggs, Kevin M Cottrell, Matthew R Tonini, et al.
Page
of 8